↓ Skip to main content

Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson’s Disease, Glioma, and Schwannoma

Overview of attention for article published in Cellular and Molecular Neurobiology, March 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (87th percentile)
  • High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

twitter
3 X users
patent
6 patents

Citations

dimensions_citation
87 Dimensions

Readers on

mendeley
183 Mendeley
Title
Delivery of Therapeutic Proteins via Extracellular Vesicles: Review and Potential Treatments for Parkinson’s Disease, Glioma, and Schwannoma
Published in
Cellular and Molecular Neurobiology, March 2016
DOI 10.1007/s10571-015-0309-0
Pubmed ID
Authors

Justin Hall, Shilpa Prabhakar, Leonora Balaj, Charles P. Lai, Richard A. Cerione, Xandra O. Breakefield

Abstract

Extracellular vesicles present an attractive delivery vehicle for therapeutic proteins. They intrinsically contain many proteins which can provide information to other cells. Advantages include reduced immune reactivity, especially if derived from the same host, stability in biologic fluids, and ability to target uptake. Those from mesenchymal stem cells appear to be intrinsically therapeutic, while those from cancer cells promote tumor progression. Therapeutic proteins can be loaded into vesicles by overexpression in the donor cell, with oligomerization and membrane sequences increasing their loading. Examples of protein delivery for therapeutic benefit in pre-clinical models include delivery of: catalase for Parkinson's disease to reduce oxidative stress and thus help neurons to survive; prodrug activating enzymes which can convert a prodrug which crosses the blood-brain barrier into a toxic chemotherapeutic drug for schwannomas and gliomas; and the apoptosis-inducing enzyme, caspase-1 under a Schwann cell specific promoter for schwannoma. This therapeutic delivery strategy is novel and being explored for a number of diseases.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 183 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Denmark 1 <1%
Germany 1 <1%
Unknown 180 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 32 17%
Student > Bachelor 26 14%
Student > Master 24 13%
Researcher 21 11%
Student > Doctoral Student 11 6%
Other 31 17%
Unknown 38 21%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 40 22%
Agricultural and Biological Sciences 30 16%
Medicine and Dentistry 22 12%
Neuroscience 14 8%
Engineering 7 4%
Other 26 14%
Unknown 44 24%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2023.
All research outputs
#2,415,137
of 24,892,887 outputs
Outputs from Cellular and Molecular Neurobiology
#53
of 1,077 outputs
Outputs of similar age
#38,394
of 306,839 outputs
Outputs of similar age from Cellular and Molecular Neurobiology
#6
of 55 outputs
Altmetric has tracked 24,892,887 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,077 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,839 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 87% of its contemporaries.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.